Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -60.93% is 60% above its 5-year average of -152.09%, near the high end of its 5-year range (-354.19%–-25.73%).
61.98% above its 12-month average of -160.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -18.92%.
RETURN ON ASSETS (ROA)
-60.93%
RETURN ON ASSETS (ROA) AVG TTM
-160.25%
RETURN ON ASSETS (ROA) AVG 3Y
-205.49%
RETURN ON ASSETS (ROA) AVG 5Y
-152.09%
RETURN ON ASSETS (ROA) AVG 10Y
-121.23%
RETURN ON ASSETS (ROA) AVG 15Y
-96.07%
RETURN ON ASSETS (ROA) AVG 20Y
-105.65%
CURRENT VS TTM AVG
+61.98%
CURRENT VS 3Y AVG
+70.35%
CURRENT VS 5Y AVG
+59.94%
CURRENT VS 10Y AVG
+49.74%
CURRENT VS 15Y AVG
+36.58%
CURRENT VS 20Y AVG
+42.33%
SECTOR MEDIAN · HEALTHCARE
-23.71%
median of 389 covered companies
CURRENT VS SECTOR MEDIAN
-156.98%
vs the sector median at left
Cellectar Biosciences, Inc.
Market Cap
$13.34M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$12.63M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$12.46M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$14.28M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$11.95M
Return on Assets (ROA)
N/A
TTM Avg
-37.02%
3Y Avg
-41.41%
5Y Avg
-41.74%
Market Cap
$11.42M
Return on Assets (ROA)
-198.70%
TTM Avg
-189.50%
3Y Avg
-187.22%
5Y Avg
-200.18%
Market Cap
$11.41M
Return on Assets (ROA)
-26.45%
TTM Avg
-58.62%
3Y Avg
-47.64%
5Y Avg
-51.16%
Market Cap
$15.30M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
Market Cap
$11.01M
Return on Assets (ROA)
-77.94%
TTM Avg
-178.68%
3Y Avg
-1009.31%
5Y Avg
-2782.57%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $13.34M | -60.93% | -160.25% | -205.49% | -152.09% |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | -49.12% | -29.80% | -67.98% | -117.36% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | -47.98% | -31.15% | -42.27% | -34.21% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | -32.53% | -31.07% | -30.77% | -29.89% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | N/A | -37.02% | -41.41% | -41.74% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | -198.70% | -189.50% | -187.22% | -200.18% |
| Biofrontera Inc. (BFRI)vs › | $11.41M | -26.45% | -58.62% | -47.64% | -51.16% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -213.77% | -110.51% | -93.41% | -68.22% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -77.94% | -178.68% | -1009.31% | -2782.57% |
| BioVie Inc. (BIVI)vs › | $10.86M | -154.89% | -40.68% | -87.98% | -439.28% |
ROA
-60.9%
ROE
-74.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -145.48% |
| 2024-12-31 | -175.01% |
| 2023-12-31 | -354.19% |
| 2022-12-31 | -147.26% |
| 2021-12-31 | -64.84% |
| 2020-12-31 | -25.73% |
| 2019-12-31 | -115.04% |
| 2018-12-31 | -87.94% |
| 2017-12-31 | -105.37% |
| 2016-12-31 | -40.33% |
| 2015-12-31 | -72.34% |
| 2014-12-31 | -60.41% |
| 2013-12-31 | -158.19% |
| 2012-12-31 | -76.64% |
| 2011-12-31 | -70.39% |
| 2010-12-31 | 85.16% |
| 2009-12-31 | -249.37% |
| 2008-12-31 | -1122.17% |
| 2007-12-31 | -176.07% |
| 2006-12-31 | -69.49% |
| 2005-12-31 | -61.83% |
| 2004-12-31 | -750.92% |
